WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the period ended March 31, 2021 and reviewed recent business highlights.
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced today that it will present new data on the company’s scaled cGMP cell therapy manufacturing program at the 2021 American Society for Gene and Cell Therapy Virtual Annual Meeting (ASGCT) from May 11-14. The company will also present findings on the performance advantages of cells engineered through its proprietary Cell Squeeze® Technology.
While use of the gaming technology for improving physical ailments is still in the early stages, it shows promise — and it’s fun.
This article is part of our new series on the Future of Health Care, which examines changes in the medical field.
Four years ago, Michael Heinrich was riding his motorcycle on the University of Michigan campus when a rotted tree fell on him and snapped his neck, causing him to permanently lose use of the lower half of his body. He spent weeks in intensive care and then went to inpatient rehabilitation for more than two months,
About halfway through his rehab stint, his occupational therapist, Michael Blackstock, asked whether he was interested in trying virtual reality for his therapy. Mr. Heinrich, now 26 — who is returning for his master’s at the university — was game.
“What I really enjoyed was being an eagle trying to go through rings,” he said, describing a virtual reality experience. “From an emotional standpoint, coming off an injury where I lost the majority of the use of my body, V.R. pushed the boundaries of what I thought was possible.”
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights.
“In 2020, we experienced the most important moment in SQZ’s journey so far: dosing our first patient. This accomplishment was coupled with exciting progress across our pipeline and the transition to being a public company. Despite the many challenges of COVID-19, our team continued to maintain focus on our mission to create transformative cell therapies for patients, for which I am proud and thankful,” commented Armon Sharei, chief executive officer. “We have many exciting milestones ahead and are committed to delivering on SQZ’s potential for patients across diseases.”
Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inherited and neurological disorders. The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners. Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.